Medivir AB, a leading pharmaceutical company focused on developing cutting-edge treatments for cancer, is presenting a poster today at the AACR Annual Meeting that highlights the powerful results of a triple combination of its drug fostrox (MIV-818) with immune checkpoint and kinase inhibition.
The poster, entitled ‘A triple combination of fostrox (MIV-818) with immune checkpoint and kinase inhibition shows increased anti-tumor efficacy in vivo,’ was presented by Fredrik Öberg, CSO at Medivir. These promising findings demonstrate the potential of this treatment in the fight against cancer, and further highlights Medivir’s commitment to providing treatments with high unmet medical need.
Fostroxacitabine bralpamide (fostrox) is an innovative, orally administered prodrug that is being evaluated in a phase 1/2a clinical study for its potential to treat advanced hepatocellular carcinoma (HCC). It has shown promising results in combination with Keytruda® (anti-PD1) or Lenvima® (kinase inhibitor) in non-clinical trials, and researchers are now exploring the potential of a triple combination with Fostrox to achieve an even further enhanced anti-tumor effect.
Medivir AB, a leader in oncology research and development, is presenting a groundbreaking poster today at the AACR Annual Meeting that showcases the immense power of a triple combination of its drug fostrox (MIV-818) with immune checkpoint and kinase inhibition.
The poster, titled ‘A triple combination of fostrox (MIV-818) with immune checkpoint and kinase inhibition shows increased anti-tumor efficacy in vivo’ and presented by Fredrik Öberg, CSO at Medivir, provides a hopeful glimpse into the future of cancer treatment. This promising discovery is a testament to Medivir’s commitment to providing treatments for diseases with high unmet medical needs.
Medivir’s Fostrox offers a unique, liver-targeted approach to treating HCC, making it a promising addition to existing combination treatments. Combining its action with three different approaches could lead to improved outcomes for far more patients, giving them the chance to gain satisfactory results from their treatment. With Fostrox, new combinations are now possible, offering a real opportunity to revolutionize the way HCC is managed.
The presentation will unveil a stunning poster showcasing Medivir’s latest breakthrough! Make sure to keep an eye out for it on their website after the presentation is over.
Fostrox is an innovative pro-drug that has the potential to revolutionize the treatment of liver cancer. By selectively targeting liver cancer cells and reducing side effects, Fostrox is poised to become the first orally administered medication for patients with HCC and other forms of liver cancer.
The drug has successfully completed a phase 1b monotherapy study, and a combination study in HCC is currently underway. This exciting development offers a ray of hope to those affected by this devastating disease.
About primary liver cancer
Primary liver cancer is an often deadly disease, claiming the lives of thousands of people around the world each year. Hepatocellular carcinoma (HCC) is the most common form of the disease, yet current treatments are inadequate in providing relief and extending the lives of those affected. In the United States alone, 42,000 people are diagnosed with HCC each year, yet the five-year survival rate is just 11 percent.
This is largely due to the lack of defining mutations observed in other cancers, making it difficult to develop effective molecularly targeted treatments. The urgent need for better treatments is clear, with a large unmet medical need for those with intermediate and advanced HCC.
Medivir is a leading pharmaceutical company dedicated to delivering life-saving treatments to those suffering from cancer. Our cutting-edge drug candidates are designed to provide significant improvements to patients, specifically targeting indications with limited or missing therapies. Fostroxacitabine bralpamide (fostrox) is our lead pro-drug designed to selectively treat liver cancer cells and minimize side effects.
Through our collaborations and partnerships, we have outlicensed Birinapant, a SMAC mimetic, to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Our shares (ticker: MVIR) are listed on Nasdaq Stockholm’s Small Cap list, and we are proud to be making a difference to people’s lives.